Exclusive NASDAQ MarketSite Interview with Aethlon Medical Inc. (NASDAQ: AEMD) CEO James Joyce

Business New – Financial News – New York Stock Exchange — Wall Street — CEO Interview — 2016 — Stock News

Best Biotech Stock – Best Medical Device Stock – Biotech Stock 2016 – Medical Device Stock 2016

Aethlon Medical Inc. (NASDAQ: AEMD)

CLICK HERE➡ ➡ http://FinancialBuzz.com

Business News – Financial News – Stock News — New York Stock Exchange — Market News 2016

Business News – Financial News – Stock Exchange — Wall Street — Market News – New York Stock Exchange 2016

About Financial Buzz Media
http://FinancialBuzz.com was designed to provide information on latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

Financial Buzz Media provides credible branding, marketing and advertising through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, TV Broadcasting, and Financial Publications. In a public financial market that requires extensive transparency and disclosures, Financial Buzz Media provides one of the most internationally credible media outlets by reporting live from various locations; The New York Stock Exchange, NASDAQ Exchange and Hong Kong Exchange.

For “the latest buzz in financial news” every day, please visit http://FinancialBuzz.com

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. The Aethlon Hemopurifier® is a leading broad-spectrum treatment countermeasure against infectious viral pathogens. The device, which has been successfully administered to individuals infected with HIV, Hepatitis C (HCV) and Ebola virus, is currently the subject of FDA approved clinical studies. Aethlon is also studying the potential use of the Hemopurifier® to address exosomes secreted by tumors to promote the spread of metastasis and suppress the immune system of cancer patients. The Company provides government contracting services to the Defense Advanced Research Projects Agency (DARPA) related to the development of a biofiltration device to treat sepsis and maintains majority ownership of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor Chronic Traumatic Encephalopathy (CTE) and other neurological disorders. Additional information can be found online at www.AethlonMedical.com

© 2011 Financial Buzz. All rights reserved. No portion of this video or FinancialBuzz.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law.

Post Author: Technology Media